SG11202106169SA - Cell composition comprising liver progenitor cells expressing hla-e - Google Patents

Cell composition comprising liver progenitor cells expressing hla-e

Info

Publication number
SG11202106169SA
SG11202106169SA SG11202106169SA SG11202106169SA SG11202106169SA SG 11202106169S A SG11202106169S A SG 11202106169SA SG 11202106169S A SG11202106169S A SG 11202106169SA SG 11202106169S A SG11202106169S A SG 11202106169SA SG 11202106169S A SG11202106169S A SG 11202106169SA
Authority
SG
Singapore
Prior art keywords
cells expressing
progenitor cells
cell composition
expressing hla
liver progenitor
Prior art date
Application number
SG11202106169SA
Inventor
Jean-Leon Tchelingerian
Elisa Corritore
Giuseppe Mazza
Nathalie Belmonte
Etienne Sokal
Original Assignee
Promethera Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promethera Therapeutics Sa filed Critical Promethera Therapeutics Sa
Publication of SG11202106169SA publication Critical patent/SG11202106169SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C12N5/0672—Stem cells; Progenitor cells; Precursor cells; Oval cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
SG11202106169SA 2018-12-14 2019-12-12 Cell composition comprising liver progenitor cells expressing hla-e SG11202106169SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2018085024 2018-12-14
PCT/EP2019/084868 WO2020120664A1 (en) 2018-12-14 2019-12-12 Cell composition comprising liver progenitor cells expressing hla-e

Publications (1)

Publication Number Publication Date
SG11202106169SA true SG11202106169SA (en) 2021-07-29

Family

ID=64900876

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106169SA SG11202106169SA (en) 2018-12-14 2019-12-12 Cell composition comprising liver progenitor cells expressing hla-e

Country Status (13)

Country Link
US (1) US20220049225A1 (en)
EP (1) EP3894542A1 (en)
KR (1) KR20210116469A (en)
CN (1) CN113316633A (en)
AU (1) AU2019398753A1 (en)
BR (1) BR112021011273A2 (en)
CA (1) CA3122715A1 (en)
EA (1) EA202191673A1 (en)
IL (1) IL283867A (en)
MX (1) MX2021006773A (en)
SG (1) SG11202106169SA (en)
TW (1) TW202043463A (en)
WO (1) WO2020120664A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113316633A (en) * 2018-12-14 2021-08-27 普罗米瑟拉疗法公司 Cell compositions comprising HLA-E expressing hepatic progenitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL155249A0 (en) * 2000-10-03 2003-11-23 Univ North Carolina Methods of isolating bipotent hepatic progenitor cells
PL1969118T5 (en) 2005-12-21 2015-06-30 Univ Catholique Louvain Isolated liver stem cells
US8647871B2 (en) * 2007-03-30 2014-02-11 Escape Therapeutics, Inc. Endogenous expression of HLA-G and/or HLA-E by mesenchymal cells
US8709401B2 (en) 2011-02-25 2014-04-29 Howmedica Osteonics Corp. Primed stem cells and uses thereof to treat inflammatory conditions in joints
EP2880054B1 (en) * 2012-07-31 2019-01-16 Escape Therapeutics, Inc. Hla g-modified cells and methods
AU2014314152B2 (en) 2013-08-28 2020-02-06 Promethera Therapeutics Sa Method for producing adult liver progenitor cells
PL3140393T3 (en) 2014-08-28 2023-11-06 Cellaïon SA Method for producing adult liver progenitor cells
CA3202385A1 (en) * 2014-12-30 2016-07-07 The Brigham And Women's Hospital, Inc. Methods to improve cell therapy
MA45274A (en) 2016-03-02 2019-01-09 Univ Catholique Louvain IMPROVED ADULT HEPATIC PROGENITOR CELL PREPARATIONS
EP3532606A4 (en) 2016-10-27 2020-07-29 The Trustees of Columbia University in the City of New York Immunosuppressive mesenchymal cells and methods for forming same
WO2020120666A1 (en) * 2018-12-14 2020-06-18 Promethera Biosciences S.A./N.V. Liver progenitor cells expressing hla-g, and method for obtaining these cells compositions comprising said cells and their use
CA3122715A1 (en) * 2018-12-14 2020-06-18 Promethera Therapeutics Sa Cell composition comprising liver progenitor cells expressing hla-e
US20220401477A1 (en) * 2021-05-18 2022-12-22 Verdure Biotech, Inc. Method for controlling viral infections through adoptive transfer of a cell product comprising an expanded and enriched population of superactivated cytokine killer cells
KR20230151139A (en) * 2022-04-22 2023-11-01 단국대학교 천안캠퍼스 산학협력단 Composition for preventing and ameliorating side effects induced by anticancer chemotherapeutic agent comprising Gryllus bimaculatus prepared by enzymatic hydrolysis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113316633A (en) * 2018-12-14 2021-08-27 普罗米瑟拉疗法公司 Cell compositions comprising HLA-E expressing hepatic progenitors

Also Published As

Publication number Publication date
EA202191673A1 (en) 2021-09-28
KR20210116469A (en) 2021-09-27
CN113316633A (en) 2021-08-27
BR112021011273A2 (en) 2021-09-28
MX2021006773A (en) 2021-09-21
JP2022513475A (en) 2022-02-08
AU2019398753A1 (en) 2021-08-05
WO2020120664A1 (en) 2020-06-18
US20220049225A1 (en) 2022-02-17
CA3122715A1 (en) 2020-06-18
TW202043463A (en) 2020-12-01
IL283867A (en) 2021-07-29
EP3894542A1 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
IL287553B1 (en) Modified pluripotent cells
EP3479431A4 (en) Solid electrolyte compositions
EP3292578A4 (en) Electrochemical hydrogen storage electrodes and cells
EP3601159A4 (en) Solid electrolyte material and solid-state battery made therewith
EP3486981A4 (en) Binder composition for solid electrolyte batteries
EP3575375A4 (en) Latent-heat storage material composition and latent-heat storage tank
EP3471182A4 (en) Binder composition for solid electrolyte batteries and slurry composition for solid electrolyte batteries
IL272134A (en) Electrolyte composition, electrolyte film, and cell
EP3297950A4 (en) Stable basic electrolyte material and solvent material containing same
IL286776A (en) Compositions and methods for preparing t cell compositions and uses thereof
EP3332439A4 (en) Flow battery electrolyte compositions containing an organosulfate wetting agent and flow batteries including same
EP3704757A4 (en) Electrolyte composition
EP3633779A4 (en) Electrolyte composition and rechargeable battery
EP3309882A4 (en) Cathode composition, cathode and fuel cell including same
IL283867A (en) Cell composition comprising liver progenitor cells expressing hla-e
GB201710655D0 (en) Electrochemical cell
PT3899996T (en) Electrolyte compositions
EP3890045A4 (en) Electrochemical cell
EP3214171A4 (en) Placenta-derived cells excreting c3 or c1r complement and composition containing same
GB201704968D0 (en) Transduced cell formulation
HUE062232T2 (en) Solid electrolyte composition
EP3726550A4 (en) Electrolyte composition and use thereof
TWI848946B (en) Use of composition containing xenogeneic urothelial cell
GB2570892B (en) Electrochemical cell stack
EP3817084A4 (en) Electrochemical cell